| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ratings for Janux Therapeutics (NASDAQ:JANX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Janux Therapeutics, presenting an average target of $62.75, a high estimate of $100.00, and a low estimate of $48.00. Marking an increase of 126.78%, the current average surpasses the previous average price target of $27.67.
The standing of Janux Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Josh Schimmer | Cantor Fitzgerald | Announces | Overweight | $100.00 | - |
| Geoff Meacham | B of A Securities | Raises | Buy | $48.00 | $24.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $50.00 | $35.00 |
| David Driscoll | Wedbush | Raises | Outperform | $53.00 | $24.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Janux Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Janux Therapeutics analyst ratings.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Janux Therapeutics faced challenges, resulting in a decline of approximately -13.5% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Janux Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -477.77%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Janux Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.39%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.06%, the company showcases effective utilization of assets.
Debt Management: Janux Therapeutics's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: JANX
